

Press Release

12 April 2023 14:30:00 CEST

2cureX presents preliminary Q1 2023 commercial results.

2cureX will today, at a Q&A session, present commercial results for Q1 2023 and other important achievements in this quarter.

In summary Q1 2023 has been an active quarter with achievements that are in line with the forecasted goals, except for the number of samples tested, which is slightly lower than forecasted. Other important achievements are above our expectations. We therefore maintain our commercial goals for the full year of 2023.

2023 commercial goals:

Revenue: 6M SEK (0.8 m SEK in Q1)

Commercial rollout: 25 countries with IndiTreat® commercial activities (20 countries in Q1)

Samples tested: 500 patient samples (25 samples in Q1)

Preliminary results for Q1 2023 related to the yearly goals:

Revenue: 0.76 M SEK

Commercial rollout: 20 countries with active IndiTreat® activities

Samples tested: 18 patient samples

Other important achievements in Q1 2023:

A highly successful ISO13485 Audit.

Launch of an updated Specimen Collection Set

IGNITE sites grew from 24 to 27

2cureX received together with technology partners, a prestigious grant (1 M EUR) from the German Federal Ministry of Education and Research to support the automation project.

2cureX received an innovation grant (1.5 M DKK) from the Danish Innovation Foundation Fund to support the development of IndiTreat® Neo.

Strengthened communication activities involving events hosted by Infront Direkt and Stokk.io, a new website, monthly Newsletters and CEO Blogs

The official Q1 2023 report will be published on May 25, 2023.

A Q&A session to present these results in detail, as well as answering questions from the audience, will be held at 20:00 (CET) tonight. You can sign-up for the event with link: [Q&A webcast for Q1 2023](#)).

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer

E-mail: fa@2curex.com

Telephone: +45 2279 5399

www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

Attachments

[2cureX presents preliminary Q1 2023 commercial results.](#)